KLF13 promotes VSMCs phenotypic dedifferentiation by directly binding to the SM22α promoter
Journal of Cellular Physiology · 2024
DOI: 10.1002/jcp.31251 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular Physiology, 2024. Verfasst von Xiaofan Yuan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Practice, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, C…. Hauptthemen laut MEDLINE: Cell Dedifferentiation, Cell Proliferation, Kruppel-Like Transcription Factors, Muscle Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Key Research and Development Program of Sichuan Province, Natural Science Foundation of Sichuan Province.
Abstract (Originalsprache)
Krüppel‐like factor 13 (KLF13), a zinc finger transcription factor, is considered as a potential regulator of cardiomyocyte differentiation and proliferation during heart morphogenesis. However, its precise role in the dedifferentiation of vascular smooth muscle cells (VSMCs) during atherosclerosis and neointimal formation after injury remains poorly understood. In this study, we investigated the relationship between KLF13 and SM22α expression in normal and atherosclerotic plaques by bioanalysis, and observed a significant increase in KLF13 levels in the atherosclerotic plaques of both human patients and ApoE −/− mice. Knockdown of KLF13 was found to ameliorate intimal hyperplasia following carotid artery injury. Furthermore, we discovered that KLF13 directly binds to the SM22α promoter, leading to the phenotypic dedifferentiation of VSMCs. Remarkably, we observed a significant inhibition of platelet‐derived growth factor BB‐induced VSMCs dedifferentiation, proliferation, and migration when knocked down KLF13 in VSMCs. This inhibitory effect of KLF13 knockdown on VCMC function was, at least in part, mediated by the inactivation of p‐AKT signaling in VSMCs. Overall, our findings shed light on a potential therapeutic target for treating atherosclerotic lesions and restenosis after vascular injury.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Practice, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
- Department of Neurosurgery, The Southwest Medical University, Luzhou, Sichuan, China.
- Department of Cardiology, Peking University Third Hospital, Beijing, China.
- Department of Neurology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
- Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
ORCID-Profile: Xiaofan Yuan
Förderung
- Key Research and Development Program of Sichuan Province
- Natural Science Foundation of Sichuan Province
Zitieren
APA
Yuan, X., Jiang, C., Xue, Y., Guo, F., Luo, M., Guo, L., Gao, Y., Yuan, T., Xu, H., & Chen, H. (2024). KLF13 promotes VSMCs phenotypic dedifferentiation by directly binding to the SM22α promoter. Journal of Cellular Physiology. https://doi.org/10.1002/jcp.31251
Vancouver
Yuan X, Jiang C, Xue Y, Guo F, Luo M, Guo L, et al. KLF13 promotes VSMCs phenotypic dedifferentiation by directly binding to the SM22α promoter. Journal of Cellular Physiology. 2024. doi:10.1002/jcp.31251
BibTeX
@article{Yuan2024,
author = {Yuan, Xiaofan and Jiang, Chuan and Xue, Yuzhou and Guo, Fuqiang and Luo, Minghao and Guo, Lei and Gao, Yang and Yuan, Tongling and Xu, Hui and Chen, Hong},
title = {KLF13 promotes VSMCs phenotypic dedifferentiation by directly binding to the SM22α promoter},
journal = {Journal of Cellular Physiology},
year = {2024},
doi = {10.1002/jcp.31251}
}
EUVIMED